Who is sponsoring NCT00685698?

NCT00685698 is sponsored by TaiGen Biotechnology Co., Ltd..

What drugs are being tested in NCT00685698?

Interventions in NCT00685698: TG-873870 (Nemonoxacin).

What condition does NCT00685698 study?

NCT00685698 studies Diabetic Foot Infections.

Is NCT00685698 still recruiting?

NCT00685698 is currently completed. Last updated 13 June 2025.

Are results published for NCT00685698?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-06-13 · How we verify

NCT00685698

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens

Completed Phase 2 Results posted Last updated 13 June 2025

What this trial tests

Phase 2 trial testing TG-873870 (Nemonoxacin) in Diabetic Foot Infections in 40 participants. Completed in 1 June 2009.

Timeline

1 June 2008

Primary endpoint
1 April 2009

1 June 2009

Quick facts

Lead sponsor	TaiGen Biotechnology Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 June 2008
Primary completion	1 April 2009
Estimated completion	1 June 2009
Sites	16 locations across United States, South Africa, Taiwan, Thailand

Drugs / interventions tested

TG-873870 (Nemonoxacin) — full drug profile →

Conditions studied

Diabetic Foot Infections — all drugs for Diabetic Foot Infections →

Sponsor

TaiGen Biotechnology Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Diabetic Foot Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical Success (in ITT Population)
Time frame: Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination
Clinical Success * Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection. * Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment,

Sponsor's own description

Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance.
Vanamala K, Tatiparti K, Bhise K, Sau S, et al · · 2021 · cited 34× · PMID 33091564 · DOI 10.1016/j.drudis.2020.10.011
Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.
Koulenti D, Xu E, Song A, Sum Mok IY, et al · · 2020 · cited 27× · PMID 32019171 · DOI 10.3390/microorganisms8020191

Verify or expand the search:

Other TaiGen Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT07415304 — A Phase 1 Study of ISM4808 in Healthy Adult Subjects · Phase 1 · not yet recruiting
NCT04706468 — To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenz · Phase 2 · completed
NCT04495322 — To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effec · Phase 1 · completed
NCT05133752 — Oral Nemonoxacin in Treating Elderly Patients With CAP · Phase 4 · completed
NCT03362853 — A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhy · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00685698 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TaiGen Biotechnology Co., Ltd.
Last refreshed: 13 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00685698.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing